Solana (SOL) is down about 74% from its January 2025 peak, but is still up more than 100x since launch in early 2020. The article highlights Solana’s payment/DeFi use case—3,641 TPS at fractions of a penny per transaction, ~$4.9B in total value locked, and payment-related partnerships/use by Shopify, Visa, PayPal, and Stripe—while also flagging ongoing network outage/disruption risk. Net-net, it frames Solana as an adoption candidate in payments but recommends diversification across a basket of altcoins given long-run uncertainty and small crypto portfolio sizing.
The market is still pricing SOL like an infrastructure call option, but the value capture is not linear: most early economic benefit from crypto payments accrues to the on/off-ramp, custody, and merchant stack, while the base token remains a high-beta funding asset. That means upside can persist if adoption broadens, but the instrument is still vulnerable to sharp de-ratings whenever liquidity tightens or risk appetite fades.
The key near-term risk is reliability, not throughput. In payments, one visible disruption can matter more than a marginal speed advantage because merchants optimize for continuity and customer trust, so a single outage can stall adoption discussions for quarters. Over 1-3 months, SOL will likely trade mostly as crypto beta; over 6-18 months, the real catalyst is whether stablecoin settlement becomes a regulated, repeatable workflow rather than a pilot.
The consensus is probably overestimating how much of that upside accrues to SOL itself. If Solana-based checkout becomes relevant, the clearer beneficiaries are regulated rails and merchant platforms that can absorb crypto settlement without sacrificing fee durability, while PayPal faces more execution risk if it chases lower-fee flows. Net: the article supports a selective payments-rail view, not an aggressive standalone SOL thesis.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
mixed
Sentiment Score
-0.05
Ticker Sentiment